Gilles Quere

Brest, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications

Sex-specific Risks in Lung Cancer-Associated Thrombosis: Focus on Female Patients.

Sex-specific Risks in Lung Cancer-Associated Thrombosis: Focus on Female Patients.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Published: July 31, 2026

PRognostic and predictive potential Of multiparametric dynamic whole-body 18F-FDG PET Imaging using a Long axial field-of-view (LAFOV) system for FIRST-line chemo-immunotherapy efficacy in advanced non-small cell lung cancer: PROFIL-1 study protocol.

PRognostic and predictive potential Of multiparametric dynamic whole-body 18F-FDG PET Imaging using a Long axial field-of-view (LAFOV) system for FIRST-line chemo-immunotherapy efficacy in advanced non-small cell lung cancer: PROFIL-1 study protocol.

Journal: PloS one
Published: November 11, 2025

Real-life Experience of Rare Hepatoid Adenocarcinomas of the Lung: A Large Retrospective French Cohort.

Real-life Experience of Rare Hepatoid Adenocarcinomas of the Lung: A Large Retrospective French Cohort.

Journal: Clinical lung cancer
Published: March 25, 2025

Uncommon MET mutational landscape in a non-small cell lung cancer patient treated with crizotinib: Case report.

Uncommon MET mutational landscape in a non-small cell lung cancer patient treated with crizotinib: Case report.

Journal: Heliyon
Published: September 12, 2023

Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29).

Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29).

Journal: Translational lung cancer research
Published: July 26, 2022

Real-life second-line epirubicin-paclitaxel regimen as treatment of relapsed small-cell lung cancer: EpiTax study.

Real-life second-line epirubicin-paclitaxel regimen as treatment of relapsed small-cell lung cancer: EpiTax study.

Journal: Cancer medicine
Published: January 25, 2022

Toxicity after volumetric modulated arc therapy for lung cancer: a monocentric retrospective study.

Toxicity after volumetric modulated arc therapy for lung cancer: a monocentric retrospective study.

Journal: Translational lung cancer research
Published: February 11, 2021

Vascular Acrosyndromes Associated With Prolonged Tumor Response in Advanced Lung Cancer Patients During Treatment With Antimetabolites: A Report of Two Cases.

Vascular Acrosyndromes Associated With Prolonged Tumor Response in Advanced Lung Cancer Patients During Treatment With Antimetabolites: A Report of Two Cases.

Journal: Frontiers in oncology
Published: December 20, 2020

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019.

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019.

Journal: Cancers
Published: November 06, 2020

Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study.

Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study.

Journal: Cancer immunology, immunotherapy : CII
Published: September 21, 2020

Henoch-Schönlein Purpura Associated with Lung Cancer: When Paraneoplastic Manifestations Impede Oncological Management.

Henoch-Schönlein Purpura Associated with Lung Cancer: When Paraneoplastic Manifestations Impede Oncological Management.

Journal: Case reports in immunology
Published: August 02, 2020

PD-L1 Copy Number Variation Does Not Correlate With PD-L1 Expression or Response to Anti-PD-1 Immunotherapy In Patients With Advanced Melanomas.

PD-L1 Copy Number Variation Does Not Correlate With PD-L1 Expression or Response to Anti-PD-1 Immunotherapy In Patients With Advanced Melanomas.

Journal: Applied immunohistochemistry & molecular morphology : AIMM
Published: February 12, 2020
Showing 1-12 of 36

Last Updated: 09/26/2026